Sunday, September 25

5:00pm–7:00pm

On-Site Pre-Registration

Monday, September 26

8:00am–8:30

Registration & Continental Breakfast

8:30–8:50

Welcome and Opening Remarks

Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

8:50–9:30

Plenary: From Academic Discovery Towards an FDA Approval for a Novel Amyloid Imaging Agent

Daniel M. Skovronsky, MD, PhD, Avid Radiopharmaceuticals, Inc.

I. Targeting Tau for Alzheimer’s Disease and Related Dementias
Chair: Illana Gozes, PhD, Allon Therapeutics Inc.

9:30–9:35

Session Overview

Illana Gozes, PhD, Allon Therapeutics Inc.

9:35–9:55

The Discovery and Preclinical Progress of the Neuroprotective Peptide, davunetide, in the Treatment of Tauopathies

Illana Gozes, PhD, Allon Therapeutics

9:55–10:05

Q&A

10:05–10:25

Modulating the Hsp70/DnaJ Protein Interface to Dictate Triage Decisions for Tau

Chad Dickey, PhD, University of South Florida

10:25–10:35

Q&A

10:35–11:05

BREAK

11:05–11:25

Developing a Tau Imaging Agent for Alzheimer’s Disease

Jeff Kuret, PhD, Ohio State University

11:25–11:35

Q&A

11:35–11:55

Targeting Tau Oligomers through Immunotherapy

Rakez Kayed, PhD, University of Texas Medical Branch

11:55am–12:05pm

Q&A

12:05–12:25

Tau Clearance by Autophagy

Karen Duff, PhD, Columbia University

12:25–12:35

Q&A

12:35–1:30

LUNCH & POSTER SESSION 

II. Inflammation, Chaperones, and Novel Targets
Chair: D. Martin Watterson, PhD, Northwestern University

1:30–1:35

Session Overview

D. Martin Watterson, PhD, Northwestern University

1:35–1:55

Design and Refinement of Novel Small Molecule Compounds Targeting Proinflammatory Cytokine Overproduction: A Potential Disease-Modifying Therapeutic Approach to CNS Diseases

D. Martin Watterson, PhD, Northwestern University

1:55–2:05

Q&A

2:05–2:25

Optimizing New Drug Candidates for Protein Disulfide Isomerase, A Novel Target for Neurodegenerative Diseases

Donald C. Lo, PhD, Duke University Medical Center

2:25–2:35

Q&A

2:35–2:55

Proof-of-Concept That Small Molecule Structure Correctors Are Capable of Abolishing the Detrimental Effects of Apolipoprotein E4 in Vitro by Inhibiting Domain Interaction

Robert W. Mahley, MD, PhD, Gladstone Institute for Neurological Disease and University of California, San Francisco

2:55–3:05

Q&A

3:05–3:35

BREAK

3:35–3:55

Tau Lowering Agents for the Treatment of Alzheimer’s Disease

Allen Reitz, PhD, ALS Biopharma, LLC

3:55–4:05

Q&A

4:05–4:25

Modulation of Ganglioside Catabolism Using Pharmacological Chaperones: A Novel Therapeutic Approach for Alzheimer’s Disease

Brandon Wustman, PhD, Amicus Therapeutics, Inc.

4:25–4:35

Q&A

4:35–4:55

Heat Shock Protein 90 in Neurodegenerative Diseases

Gabriela Chiosis, PhD, Memorial Sloan Kettering Cancer Center

4:55–5:05

Q&A

5:05–5:10

Closing Remarks

Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation

5:10–7:00

NETWORKING RECEPTION & POSTER SESSION

Tuesday, September 27

8:00am–8:30

Continental Breakfast

8:30–9:10

Plenary: Enhancing CNS Uptake of Biologics through Molecular Engineering

Ryan J. Watts, PhD, Genentech

III. Neuroprotection and Synaptic Enhancement
Chair: Howard Fillit, MD, Alzheimer's Drug Discovery Foundation

9:10–9:15

Session Overview

Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation

9:15–9:35

Tricyclic Pyrone Compounds and Axonal Trafficking Dysfunction in AD

Eugenia Trushina, PhD, Mayo Clinic College of Medicine

9:35–9:45

Q&A

9:45–10:05

Targeting Neuronal Calcium Signaling to Halt AD-linked Synaptic Dysfunction

Grace E. Stutzmann, PhD, Rosalind Franklin University School of Medicine

10:05–10:15

Q&A

10:15–10:35

Klotho Enhances Oligodendrocyte Maturation and Myelination

Carmela R. Abraham, PhD, Boston University School of Medicine

10:35–10:45

Q&A

10:45–11:15

BREAK

11:15–11:35

Mapping the Binding Site of HDAC 2 for the Design of Novel HDAC Inhibitors Lacking Zinc Binding Group

Pavel A. Petukhov, PhD, University of Illinois at Chicago

11:35–11:45

Q&A

11:45am–12:05pm

Targeting the Neuronal Calcium Sensor (NCS) Protein, VILIP-1, for Cognitive Impairment in CNS Disorders

Karl-Heinz Braunewell, PhD, Southern Research Institute

12:05–12:15

Q&A

12:15–12:35

Efficacy of Herbal Extract, Tetramethylpyrazine, for Alzheimer’s Disease

Zhiqun Tan, MD, PhD, University of California, Irvine

12:35–12:45

Q&A

12:45–1:45

LUNCH & POSTER SESSION

IV. Accelerating Clinical Trials for Alzheimer’s Disease through Biomarkers
Chair: Tim West, PhD, C2N Diagnostics

1:45-1:50

Session Overview

Tim West, PhD, C2N Diagnostics

1:50–2:10

A Novel Application of Stable Isotope Labeling for Disease Detection and Clinical Trials in Alzheimer’s

Tim West, PhD, C2N Diagnostics

2:10–2:20

Q&A

2:20–2:40

TOMM40 Genetic Biomarker: Accelerating Drug Development for Alzheimer’s Disease and Frontotemporal Dementia

Allen D. Roses, MD, FRCP (hon.), Duke Univeristy

2:40–2:50

Q&A

2:50–3:10

CSF Biomarkers of FTLD-TDP and FTLD-Tau: A Multi-Center Study

William Hu, MD, PhD, Emory University School of Medicine

3:10–3:20

Q&A

3:20–3:50   

BREAK

3:50–4:10

Use of Targeted Multiplex Proteomic Strategies to Identify Plasma and Cerebral Spinal Fluid-Based Biomarkers in Alzheimer’s Disease

Judith Siuciak, PhD, The Biomarkers Consortium, Foundation for the National Institutes of Health

4:10–4:20

Q&A

4:20–4:40

Pilot Trial of Metformin in the Prevention of Alzheimer’s Disease

Jose A. Luchsinger, MD, MPH, Columbia University

4:40–4:50

Q&A

4:50–5:00

Closing Remarks

Howard Fillit, MD, Alzheimer’s Drug Discovery Foundation